An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK)

Status:	Active, not recruiting
Conditions:	Lung Cancer, Cancer, Lymphoma
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	15 - Any
Updated:	11/22/2018
Start Date:	March 2011
End Date:	December 2019

Phase 1b Open-label Study Of The Safety And Clinical Activity Of Crizotinib (Pf-02341066) In Tumors With Genetic Events Involving The Anaplastic Lymphoma Kinase (Alk ) Gene Locus

This is a Phase 1 trial evaluating the safety and efficacy of crizotinib in patients with
tumors except non-small cell lung cancer that are positive for ALK.

Inclusion Criteria:

- histologically or cytologically proven diagnosis of malignancy other than NSCLC

- positive for translocation or inversion event involving the ALK gene locus

- positive for ALK amplification events

- positive for ALK activating point mutations

Exclusion Criteria:

- mutations of amplifications involving the c-Met gene but not the ALK gene

- concurrent treatment on another therapeutic clinical trial

- prior therapy specifically directed against ALK

We found this trial at

sites

Comprehensive Cancer Centers of Nevada

9280 W. Sunset Road Suite 100
Las Vegas, Nevada 89148

702.952.1251